South Korean Expat Dies in Shanghai After Receiving Chinese-Made COVID-19 Vaccines

0
6

2021_3largeimg_1051919918.jpg

A South Korean woman died three days after obtaining a Chinese Sinopharm COVID-19 vaccine. In the meantime, the Chinese communist government is censoring social media posts regarding the side effects of Chinese vaccines.

According to the foreign citizens’ community and the South Korean Consulate General in Shanghai, a South Korean woman in her 40s was discovered dead at home on April 22.

South Korean news organisations According to KBS, the Korean expat in Shanghai was vaccinated on April 19 at Shanghai Tongren Hospital with COVID-19 vaccines manufactured by the Chinese state-owned company Sinopharm. Later on, she began to experience nausea and other symptoms. She had no underlying medical conditions.

According to the South Korean Consulate in Shanghai, the Shanghai police reported that there was no evidence of murder, and the family of the female expatriate suspected that the cause of death was due to the Chinese-made vaccine.

According to the paper, the news alarmed South Korean nationals in Shanghai, and many cancelled their vaccination appointments.

Chinese authorities recently estimated that 200 million doses of Chinese-made vaccines have been administered domestically. They have, however, never disclosed the number of cases of potential death linked to the vaccines or their side effects.

Internal Chinese government documents that were recently leaked listed a variety of adverse reactions to Chinese vaccinations, including serious disability and death.

Meanwhile, the Chinese government is attempting to silence social media awareness of Chinese vaccine-related deaths.

On April 20, a female netizen in Nanjing city was detained and sentenced to seven days in administrative detention by the police for making online remarks about Chinese vaccines causing death. Jiangsu Internet Police announced her arrest on its official account on the Chinese social media site Weibo, accusing her of “causing public fear.”

On April 15, a Weibo user named “Shanxia Huayezi” reported that her 28-year-old brother, a Chinese border police officer, suffered a subcutaneous haemorrhage and gum haemorrhage after receiving a Sinopharm inactivated vaccine in Shenzhen and died that day. Later that night, she posted on Weibo that she had received phone calls from her brother’s unit in the border armed police and the Shenzhen Futian Health Bureau, and her posts were quickly removed.

As of mid-April, 14 deaths and 13 cases of facial paralysis caused by Chinese-made vaccines had been registered in Hong Kong.

Because of safety problems and a lack of clarity in trial data and side effects, Chinese-made COVID-19 vaccines have sparked widespread concern.

A phase three clinical trial of the Sinovac vaccine in Brazil in January found it to be 50.4 percent successful, much lower than the Chinese company’s initial claims of 78 percent efficacy.

Sinopharm’s COVID-19 vaccine recorded 11.5 percent and 33.3 percent efficacy rates against two virus strains in phase three clinical trials in Peru in March.

Gao Fu, Director of China’s Center for Disease Control and Prevention, admitted on April 10 at China’s National Vaccine and Health Conference that China’s vaccines have “poor efficacy,” and he was thinking about combining vaccines from different technologies.

After a fully vaccinated Chinese doctor tested positive for COVID-19 in March, he indicated on Chinese television that a third dose of the vaccine could be needed to improve its efficacy.

LEAVE A REPLY

Please enter your comment!
Please enter your name here